載入...
Recent advancements in PARP inhibitors-based targeted cancer therapy
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a new class of agents with unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers. Recent FDA approval of PARPi has motivated clinical trials centered around the optimization of PARPi-associated therapies in a va...
Na minha lista:
| 發表在: | Precis Clin Med |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501589/ https://ncbi.nlm.nih.gov/pubmed/32983586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pcmedi/pbaa030 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|